Giant Biogene Holding Co., Ltd.

Equities

2367

KYG3887G1091

Personal Products

Delayed Hong Kong S.E. 11:59:37 2024-06-24 pm EDT 5-day change 1st Jan Change
45.4 HKD +4.61% Intraday chart for Giant Biogene Holding Co., Ltd. -1.52% +27.53%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Giant Biogene Holding Co., Ltd. Approves Payment of Special Dividend, Payable on July 5, 2024 CI
Giant Biogene Holding Co., Ltd. Approves Payment of Final Dividend , Payable on July 5, 2024 CI
Giant Biogene Places 33.2 Million Shares for About HK$1.63 MT
Giant Biogene’s Profit Up 47% in 2023 MT
Giant Biogene to Pay Special 0.45 Yuan per Share Dividend MT
Giant Biogene Holding Co., Ltd. Proposes Special Cash Dividend for the Year Ended 31 December 2023, Payable on 05 July 2024 CI
Giant Biogene Holding Co., Ltd. Proposes Final Ordinary Cash Dividend for the Year Ended 31 December 2023, Payable on 05 July 2024 CI
Giant Biogene Holding Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Certain Ordinary Shares of Giant Biogene Holding Co., Ltd. are subject to a Lock-Up Agreement Ending on 3-NOV-2023. CI
Giant Biogene Holding Co., Ltd. Announces Executive Changes CI
Giant Biogene Holding Co., Ltd.(SEHK:2367) added to FTSE All-World Index CI
Giant Biogene's Profit Jumps 52.5% in H1; Shares Up 4% MT
Giant Biogene Holding Co., Ltd. Announces Executive Changes CI
Giant Biogene Holding Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
XiAn Triangle Defense Appoints CFO MT
Giant Biogene Holding Co., Ltd Announces Resignation of Fan Daidi as Executive Director CI
Certain Ordinary Shares of Giant Biogene Holding Co., Ltd. are subject to a Lock-Up Agreement Ending on 3-MAY-2023. CI
Giant Biogene Logs 21% Jump in 2022 Profit MT
Giant Biogene Holding Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Giant Biogene Holding Co., Ltd.(SEHK:2367) added to S&P Global BMI Index CI
Hong Kong Stocks Rally; Giant Biogene Rises 9% in Debut MT
Giant Biogene Holding Opens 7% Higher in Hong Kong Trading Debut MT
Giant Biogene Holding Co., Ltd. has completed an IPO in the amount of HKD 549.39384 million. CI
Giant Biogene Holding Raises $63 Million in Hong Kong IPO; Price Set at Lower End of Range MT
Giant Biogene Holding Co., Ltd. has filed an IPO in the amount of HKD 626.26376 million. CI
Chart Giant Biogene Holding Co., Ltd.
More charts
Giant Biogene Holding Co Ltd is a China-based investment holding company. The Company is principally engaged the research, development, manufacture and sale of bioactive material-based beauty and health products through its subsidiaries. The Company's main products include functional skincare products and medical dressings, and they are produced with recombinant collagen as the key bioactive ingredient. The Company also develops and manufactures rare ginsenosides technology-based functional foods. The Company mainly conducts its businesses within the domestic market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
43.4 HKD
Average target price
56.01 HKD
Spread / Average Target
+29.06%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2367 Stock
  4. News Giant Biogene Holding Co., Ltd.
  5. Giant Biogene Places 33.2 Million Shares for About HK$1.63